Lucid Inc. changes name to Caliber Imaging & DiagnosticsOctober 1st 2012
Lucid Inc. is operating under a new company name - Caliber Imaging & Diagnostics Inc., or Caliber ID. The new name reflects the company’s commitment to innovating and delivering the highest-caliber identification tools for accurate, rapid diagnosis to assist in the fight against skin cancer and other diseases, according to company reports.
Cetaphil teams with Children's Skin Disease Foundation's Camp WonderOctober 1st 2012
Galderma’s Cetaphil brand is partnering with Camp Wonder, an initiative of the Children’s Skin Disease Foundation, by donating a portion of the proceeds of a special edition moisturizing cream to the camp, as well as granting $100,000 to fund camp activities.
Naqu Area Pioneer Pharma to market NovaBay's NeutroPhase cleanser in southeast AsiaOctober 1st 2012
NovaBay Pharmaceuticals has expanded its commercial partnership agreement with Naqu Area Pioneer Pharma, a Shanghai company that markets high-end pharmaceutical products into China, for the commercialization of NeutroPhase Skin and Wound Cleanser in China and other select Asian markets.
Melanoma risk in current melanoma patients demands careful, ongoing follow-upSeptember 1st 2012
About 76,000 new cases of invasive melanoma occur in the United States each year, according to the American Cancer Society, and patients who have had one melanoma have a 5 to 10 percent risk of developing another primary tumor during their lifetime. As a result of this increased melanoma risk, careful follow-up of these patients is critical, a Harvard clinician advises.
Sandoz launches first-to-file calcipotriene cream, the first generic version of DovonexSeptember 1st 2012
Sandoz has announced the introduction of its first-to-file calcipotriene cream, the first generic version of LEO Pharma’s Dovonex 0.005 percent, which is indicated for the treatment of plaque psoriasis.
ELITech Molecular Diagnostics earns FDA clearance for real-time commercial MRSA/SA testSeptember 1st 2012
ELITech Molecular Diagnostics has received FDA clearance for its MRSA/SA ELITe MGB test, a multiplex, qualitative real-time polymerase chain reaction assay for the detection of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus (MRSA) DNA purified from human nasal swab specimens.
Ellman International acquires Sandstone Medical TechnologiesSeptember 1st 2012
Ellman International, a developer of radiofrequency technology for precision surgical and aesthetic procedures, has announced its acquisition of Sandstone Medical Technologies, developer of aesthetic laser and intense pulsed light technologies.
Patricia Engasser, M.D., receives Clark W. Finnerud AwardAugust 1st 2012
The Dermatology Foundation (DF) Board of Directors recently recognized the impact that Patricia G. Engasser, M.D., has had on the specialty of dermatology by presenting her with the Clark W. Finnerud Award at its annual membership meeting in San Diego.
Cohera Medical secures Series D financing to grow TissuGlu marketsAugust 1st 2012
Cohera Medical, a developer of absorbable surgical adhesives and sealants, has secured more than $8.4 million toward Series D financing through private investors, which the company reportedly will use to expand adoption of its TissuGlu Surgical Adhesive product in Germany and additional European markets.
Wellness Center USA signs agreement to acquire Psoria-ShieldAugust 1st 2012
Wellness Center USA, a healthcare and nutraceutical company, has announced the signing of a share exchange agreement to acquire Psoria-Shield, a developer and manufacturer of ultraviolet (UV) phototherapy devices for the treatment of various skin diseases.
Verisante Technology continues funding for Aura deviceAugust 1st 2012
Verisante Technology has renewed its Collaborative Research Agreement with the BC Cancer Agency, which will include Verisante’s contribution of approximately $250,000 to fund continued development of its Aura device for skin cancer detection.
Merz appoints James P. Hartman vice president, medical dermatologyJuly 1st 2012
Merz has announced that James P. Hartman has been appointed vice president, medical dermatology, effective June 12, 2012. Mr. Hartman will be responsible for the company’s medical and OTC/OTX dermatology business unit, which includes Naftin (naftifine hydrochloride) and Mederma.
Stiefel acquires topical agent for psoriasis, atopic dermatitisJuly 1st 2012
Stiefel and Welichem Biotech have entered into an agreement for Stiefel’s acquisition of exclusive development and commercialization rights to the nonsteroidal, topical anti-inflammatory agent, WBI-1001, in all territories outside of China, Taiwan, Macao and Hong Kong.